475 related articles for article (PubMed ID: 21239968)
1. Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients.
McDonagh DL; Benedict PE; Kovac AL; Drover DR; Brister NW; Morte JB; Monk TG
Anesthesiology; 2011 Feb; 114(2):318-29. PubMed ID: 21239968
[TBL] [Abstract][Full Text] [Related]
2. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.
Plaud B; Meretoja O; Hofmockel R; Raft J; Stoddart PA; van Kuijk JH; Hermens Y; Mirakhur RK
Anesthesiology; 2009 Feb; 110(2):284-94. PubMed ID: 19194156
[TBL] [Abstract][Full Text] [Related]
3. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
[TBL] [Abstract][Full Text] [Related]
4. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.
Sparr HJ; Vermeyen KM; Beaufort AM; Rietbergen H; Proost JH; Saldien V; Velik-Salchner C; Wierda JM
Anesthesiology; 2007 May; 106(5):935-43. PubMed ID: 17457124
[TBL] [Abstract][Full Text] [Related]
5. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.
White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME
Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792
[TBL] [Abstract][Full Text] [Related]
6. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
[TBL] [Abstract][Full Text] [Related]
7. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
[TBL] [Abstract][Full Text] [Related]
8. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
de Boer HD; van Esmond J; Booij LH; Driessen JJ
Paediatr Anaesth; 2009 Dec; 19(12):1226-8. PubMed ID: 19863737
[TBL] [Abstract][Full Text] [Related]
9. Sugammadex in clinical practice.
Mirakhur RK
Anaesthesia; 2009 Mar; 64 Suppl 1():45-54. PubMed ID: 19222431
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of sugammadex for the reversal of moderate and deep rocuronium-induced neuromuscular block in patients pretreated with intravenous magnesium: a randomized controlled trial.
Czarnetzki C; Tassonyi E; Lysakowski C; Elia N; Tramèr MR
Anesthesiology; 2014 Jul; 121(1):59-67. PubMed ID: 24608361
[TBL] [Abstract][Full Text] [Related]
11. Correlation between cardiac output and reversibility of rocuronium-induced moderate neuromuscular block with sugammadex.
Yoshida F; Suzuki T; Kashiwai A; Furuya T; Konishi J; Ogawa S
Acta Anaesthesiol Scand; 2012 Jan; 56(1):83-7. PubMed ID: 22103864
[TBL] [Abstract][Full Text] [Related]
12. The use of sugammadex in a patient with myasthenia gravis.
Unterbuchner C; Fink H; Blobner M
Anaesthesia; 2010 Mar; 65(3):302-5. PubMed ID: 20105151
[TBL] [Abstract][Full Text] [Related]
13. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
[TBL] [Abstract][Full Text] [Related]
14. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
Sacan O; White PF; Tufanogullari B; Klein K
Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
[TBL] [Abstract][Full Text] [Related]
15. Neuromuscular transmission: new concepts and agents.
de Boer HD
J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
[TBL] [Abstract][Full Text] [Related]
16. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA
Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265
[TBL] [Abstract][Full Text] [Related]
17. Reversal of rocuronium-induced neuromuscular block with sugammadex in heart failure patients: a prospective observational study.
Cammu G; Coart D; De Graeve K; Beelen R
Acta Anaesthesiol Belg; 2012; 63(2):69-73. PubMed ID: 23136807
[TBL] [Abstract][Full Text] [Related]
18. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane.
Vanacker BF; Vermeyen KM; Struys MM; Rietbergen H; Vandermeersch E; Saldien V; Kalmar AF; Prins ME
Anesth Analg; 2007 Mar; 104(3):563-8. PubMed ID: 17312209
[TBL] [Abstract][Full Text] [Related]
19. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.
Rex C; Wagner S; Spies C; Scholz J; Rietbergen H; Heeringa M; Wulf H
Anesthesiology; 2009 Jul; 111(1):30-5. PubMed ID: 19512873
[TBL] [Abstract][Full Text] [Related]
20. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study.
Sorgenfrei IF; Norrild K; Larsen PB; Stensballe J; Ostergaard D; Prins ME; Viby-Mogensen J
Anesthesiology; 2006 Apr; 104(4):667-74. PubMed ID: 16571960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
